Helena M. Blumen

Dr. Helena M. Blumen

Department of Medicine, Department of Neurology, Albert Einstein College of Medicine, New York City, NY 10461, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
OJOshadi Jayakody
Oshadi Jayakody
MBMonique Breslin
Monique Breslin
EAEmmeline Ayers
Emmeline Ayers
JVJoe Verghese
Joe Verghese
NBNir Barzilai
Nir Barzilai
Helena M. BlumenHelena M. Blumen
Helena M. Blumen
Gait and cognition decline with advancing age, and presage the onset of dementia. Yet, the relative trajectories of gait and cognitive decline in aging are poorly understood—particularly among those with the motoric cognitive risk (MCR) syndrome. This study compared changes in simple and complex gait performance and cognition, as a function of age and MCR. We examined gait and cognitive functions of 1 095 LonGenity study participants (mean age = 75.4 ± 6.7 years) with up to 12 years of annual follow-up. Participants were of Ashkenazi Jewish descent, free of dementia, ambulatory, and had a 12.2% MCR prevalence at baseline. Gait speed was measured at usual pace walking (single-task walking, STW-speed) and walking while talking (WWT-speed). Eleven neuropsychological test scores were examined separately, and as a global cognition composite. Linear mixed-effects models adjusted for baseline sex, education, parental longevity, cognitive impairment, and global health were used to estimate changes in gait and cognition, as a function of age and MCR. STW-speed, WWT-speed, and cognitive tests performance declined in a nonlinear (accelerating) fashion with age. STW-speed declined faster than WWT-speed and cognitive test scores. People with MCR showed faster rates of decline on figure copy and phonemic fluency. Gait declines at a faster rate than cognition in aging. People with MCR are susceptible to faster decline in visuospatial, executive, and language functions. This study adds important knowledge of trajectories of gait and cognitive decline in aging, and identifies MCR as a risk factor for accelerated cognitive decline.

18 May 2021 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
Helena M. BlumenHelena M. Blumen
Helena M. Blumen
ESEmily Schwartz
Emily Schwartz
GAGilles Allali
Gilles Allali
OBOlivier Beauchet
Olivier Beauchet
MCMichele Callisaya
Michele Callisaya
JVJoe Verghese
Joe Verghese
Background: The motoric cognitive risk (MCR) syndrome is a pre-clinical stage of dementia characterized by slow gait and cognitive complaint. Yet, the brain substrates of MCR are not well established. Objective: To examine cortical thickness, volume, and surface area associated with MCR in the MCR-Neuroimaging Consortium, which harmonizes image processing/analysis of multiple cohorts. Methods: Two-hundred MRIs (M age 72.62 years; 47.74%female; 33.17%MCR) from four different cohorts (50 each) were first processed with FreeSurfer 6.0, and then analyzed using multivariate and univariate general linear models with 1,000 bootstrapped samples (n-1; with resampling). All models adjusted for age, sex, education, white matter lesions, total intracranial volume, and study site. Results: Overall, cortical thickness was lower in individuals with MCR than in those without MCR. There was a trend in the same direction for cortical volume (p = 0.051). Regional cortical thickness was also lower among individuals with MCR than individuals without MCR in prefrontal, insular, temporal, and parietal regions. Conclusion: Cortical atrophy in MCR is pervasive, and include regions previously associated with human locomotion, but also social, cognitive, affective, and motor functions. Cortical atrophy in MCR is easier to detect in cortical thickness than volume and surface area because thickness is more affected by healthy and pathological aging.

3 August 2020 in Neurodegenerative Disease Management
Verified
Journal Article
Closed access
Helena M. BlumenHelena M. Blumen
Helena M. Blumen
EAEmmeline Ayers
Emmeline Ayers
CWCuiling Wang
Cuiling Wang
AAAnne F Ambrose
Anne F Ambrose
JVJoe Verghese
Joe Verghese
Close to 6 million older US adults have Alzheimer's disease or related dementias, yet there is currently no cure or effective treatment. This single-blind randomized controlled trial (clinicaltrial...

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
Helena M. BlumenHelena M. Blumen
Helena M. Blumen
ESEmily Schwartz
Emily Schwartz
GAGilles Allali
Gilles Allali
OBOlivier Beauchet
Olivier Beauchet
MCMichele L Callisaya
Michele L Callisaya
JVJoe Verghese
Joe Verghese